Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

Global cancer statistics

Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results Database

Ramaswamy Govindan, Nathan Page, Daniel Morgensztern et al. · Journal of Clinical Oncology · 2006 · 1.9K citations · Full text

Medicine, Oncology, Cancer Epidemiology +15

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd et al. · Journal of Clinical Oncology · 1999 · 960 citations

Medicine, Oncology, Pharmacology +12

Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

Mary O’Brien, Tudor–Eliade Ciuleanu, H. Tsekov et al. · Journal of Clinical Oncology · 2006 · 639 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

Andrea Ardizzoni, H. Hansen, P Dombernowsky et al. · Journal of Clinical Oncology · 1997 · 481 citations

Medicine, Oncology, Pharmacology +14